For Immediate Release
Chicago, IL – September 16, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Genzyme Corp. (GENZ), Salix Pharmaceuticals (SLXP), Walt Disney Co. (DIS), Sunoco Logistics Partners LP (SXL) and Theravance (THRX).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Genzyme’s MS Drug Shows Promise
On Friday, Genzyme Corp. (GENZ) presented encouraging four-year follow-up phase II data on alemtuzumab, which is being developed for the treatment of multiple sclerosis (MS). Results showed durable reductions in relapse rate and sustained accumulation of disability even three years after patients received their last course of alemtuzumab.
Salix Scores on Rifaximin Data
Shares of Salix Pharmaceuticals (SLXP) jumped 51% after the company announced positive results from two pivotal phase III trials of rifaximin for the treatment of non-constipation irritable bowel syndrome (IBS).
Walt Disney Expands Fantasyland
The Walt Disney Co. (DIS) plans the biggest ever expansion of its Fantasyland at Florida in 2010. The planned expansion of the two franchises will be carried out in two phases, one to be completed in 2012 and the other in 2013.
Although, the exact amount to be spent on the expansion was not disclosed, Walt Disney announced plans to fund these expansions and upgrades through the Disney theme park’s annual capital expenditures.
Sunoco Logistics Acquires Pipeline
Late last week, Sunoco Logistics Partners LP (SXL) reported that it has closed the acquisition of Excel Pipeline LLC, which owns the 52-mile Excel crude oil pipeline running from Duncan to a refinery in Wynnewood, both in Oklahoma. Sunoco Logistics purchased Excel from affiliates of Gary-Williams Energy Corp., which runs the Wynnewood refinery.
Theravance on a High
In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
